Analyze the information and social media posts to determine if the closing price of $amgn will ascend or descend at 2017-03-03. Please respond with either Rise or Fall.
Context: date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-02-16,-0.3,0.0,-1.1,0.2,0.2,-1.7,-2.6,-4.7,-6.4,-7.2,-7.6
2017-02-17,-1.1,0.0,-2.5,0.7,0.7,-1.6,-2.8,-4.7,-6.5,-7.4,-7.8
2017-02-21,-0.2,0.2,-0.7,-0.1,-0.1,-0.8,-2.3,-3.9,-5.8,-6.9,-7.4
2017-02-22,-0.2,1.2,-0.4,-0.3,-0.3,-0.0,-1.6,-2.9,-4.9,-6.2,-6.9
2017-02-23,-0.7,0.0,-1.2,0.8,0.8,-0.6,-2.0,-3.1,-5.1,-6.5,-7.3
2017-02-24,-0.7,0.1,-1.2,0.3,0.3,-0.6,-1.8,-2.8,-4.7,-6.3,-7.2
2017-02-27,-1.1,0.1,-1.4,0.9,0.9,-1.2,-2.2,-3.3,-5.0,-6.6,-7.6
2017-02-28,-0.6,1.0,-0.6,0.2,0.2,-1.0,-1.9,-3.1,-4.5,-6.3,-7.4
2017-03-01,-0.1,0.8,-1.4,1.0,1.0,-1.3,-2.2,-3.6,-4.8,-6.6,-7.9
2017-03-02,-0.2,0.4,-0.7,-0.1,-0.1,-0.8,-1.8,-3.1,-4.2,-5.9,-7.3

2017-02-16: $amgn oi for maturity 02/17/2017. 155.00 highest put. 167.50 highest call.  |don't count on valeant's new drug to save the day $amgn $azn $vrx |AT_USER agree $amgn interesting, but  terms/clinical pro
2017-02-17: genentech fighting to delay looming market entry of amgen's avastin biosimilar  $rhhby $amgn|rt AT_USER biotech giants square off in 'biosimilar' fight for top-selling cancer drug  via AT_USER|genente
2017-02-18: $spx spdr health care sector etf components. $bmy $gld $unh $abbv $biib $jnj $mdt $xlv $lly $pfe $celg $mrk $tmo¡­ |rt AT_USER lobbyist for $amgn and $pfe among mar-a-lago members |$amgn oi for maturi
2017-02-19: $amgn max pain = 167.50. maturity = 02/24/2017. previous close = 173.29.   |$amgn:us mission wealth management llc purchases 30 shares of amgen inc. (amgn) #amgen inc   #nasdaq|$amgn amgen 173.29 had 
2017-02-20: $aapl $amat $amgn $amtd $amzn $atvi trade long and short positions from the #nasdaq, up to 1500% since 2010.¡­ |rt AT_USER #genentech files complaint over $amgn amgen¡¯s development of avastin biosimi
2017-02-21: AT_USER AT_USER i could see $amgn. maybe $gsk. maybe $celg tries merger of equals?|after that q4 cc i think $bmy will have a hard time fighting of AT_USER think $pfe and $nvs maybe $amgn $gild pot sui
2017-02-22: harvard pilgrim notches new agreements with $amgn and $lly |$amgn has a shot here on the monthly, too. |rt AT_USER #biotech...timeless advice......5 golden rules for better biotech investing  $abbv $a
2017-02-23: $amgn amgen wins marketing authorization for #repatha (evolocumab) single-dose delivery option  via AT_USER|rt AT_USER icymi wednesday: amgen strikes enbrel 'outcomes' contract with harvard pilgrim  $
2017-02-24: rt AT_USER bought near ipo $24.80 still own. long term wealth build rule; when get initial capital back take out invest diverse port re¡­|what should you look for in exelixis, inc. $exel 4q earnings? 
2017-02-25: $amgn max pain = 167.50. maturity = 03/03/2017. previous close = 174.56.   |3 breakout stocks for march 2017 $dal $amgn $rng |harvard pilgrim inks deal with $lly and $amgn |$amgn rose in the past few 
2017-02-27: rt AT_USER why did AT_USER lie ? cramer? $agn $vrx $myl $ibm $ko $pep $brk $iep $hlf $googl $twtr $aapl $cake $exel $hd $hiiq $hun $jpm¡­|rt AT_USER why twitter $vrx $teva $agn $myl $ko $brk $hlf $iep
2017-03-01: $amgn to present new kyprolis data at the 16th international myeloma workshop |rt AT_USER just out rbc - march madness: "reading the biotech yee-leaves" for 10 key upcoming events $amgn $vrtx $pbyi $r
2017-03-02: don't think carl didn't see these tweets! legal resolutions closer! $vrx $agn $myl $mrk $teva $spy $spx $amgn $blue¡­ |$amgn oi for maturity 03/03/2017. 167.50 highest put. 167.50 highest call.  |amge
Answer:
date,open,high,low,close,adj-close,inc-5,inc-10,inc-15,inc-20,inc-25,inc-30
2017-02-16,-0.3,0.0,-1.1,0.2,0.2,-1.7,-2.6,-4.7,-6.4,-7.2,-7.6
2017-02-17,-1.1,0.0,-2.5,0.7,0.7,-1.6,-2.8,-4.7,-6.5,-7.4,-7.8
2017-02-21,-0.2,0.2,-0.7,-0.1,-0.1,-0.8,-2.3,-3.9,-5.8,-6.9,-7.4
2017-02-22,-0.2,1.2,-0.4,-0.3,-0.3,-0.0,-1.6,-2.9,-4.9,-6.2,-6.9
2017-02-23,-0.7,0.0,-1.2,0.8,0.8,-0.6,-2.0,-3.1,-5.1,-6.5,-7.3
2017-02-24,-0.7,0.1,-1.2,0.3,0.3,-0.6,-1.8,-2.8,-4.7,-6.3,-7.2
2017-02-27,-1.1,0.1,-1.4,0.9,0.9,-1.2,-2.2,-3.3,-5.0,-6.6,-7.6
2017-02-28,-0.6,1.0,-0.6,0.2,0.2,-1.0,-1.9,-3.1,-4.5,-6.3,-7.4
2017-03-01,-0.1,0.8,-1.4,1.0,1.0,-1.3,-2.2,-3.6,-4.8,-6.6,-7.9
2017-03-02,-0.2,0.4,-0.7,-0.1,-0.1,-0.8,-1.8,-3.1,-4.2,-5.9,-7.3

2017-02-16: $amgn oi for maturity 02/17/2017. 155.00 highest put. 167.50 highest call.  |don't count on valeant's new drug to save the day $amgn $azn $vrx |AT_USER agree $amgn interesting, but  terms/clinical pro
2017-02-17: genentech fighting to delay looming market entry of amgen's avastin biosimilar  $rhhby $amgn|rt AT_USER biotech giants square off in 'biosimilar' fight for top-selling cancer drug  via AT_USER|genente
2017-02-18: $spx spdr health care sector etf components. $bmy $gld $unh $abbv $biib $jnj $mdt $xlv $lly $pfe $celg $mrk $tmo¡­ |rt AT_USER lobbyist for $amgn and $pfe among mar-a-lago members |$amgn oi for maturi
2017-02-19: $amgn max pain = 167.50. maturity = 02/24/2017. previous close = 173.29.   |$amgn:us mission wealth management llc purchases 30 shares of amgen inc. (amgn) #amgen inc   #nasdaq|$amgn amgen 173.29 had 
2017-02-20: $aapl $amat $amgn $amtd $amzn $atvi trade long and short positions from the #nasdaq, up to 1500% since 2010.¡­ |rt AT_USER #genentech files complaint over $amgn amgen¡¯s development of avastin biosimi
2017-02-21: AT_USER AT_USER i could see $amgn. maybe $gsk. maybe $celg tries merger of equals?|after that q4 cc i think $bmy will have a hard time fighting of AT_USER think $pfe and $nvs maybe $amgn $gild pot sui
2017-02-22: harvard pilgrim notches new agreements with $amgn and $lly |$amgn has a shot here on the monthly, too. |rt AT_USER #biotech...timeless advice......5 golden rules for better biotech investing  $abbv $a
2017-02-23: $amgn amgen wins marketing authorization for #repatha (evolocumab) single-dose delivery option  via AT_USER|rt AT_USER icymi wednesday: amgen strikes enbrel 'outcomes' contract with harvard pilgrim  $
2017-02-24: rt AT_USER bought near ipo $24.80 still own. long term wealth build rule; when get initial capital back take out invest diverse port re¡­|what should you look for in exelixis, inc. $exel 4q earnings? 
2017-02-25: $amgn max pain = 167.50. maturity = 03/03/2017. previous close = 174.56.   |3 breakout stocks for march 2017 $dal $amgn $rng |harvard pilgrim inks deal with $lly and $amgn |$amgn rose in the past few 
2017-02-27: rt AT_USER why did AT_USER lie ? cramer? $agn $vrx $myl $ibm $ko $pep $brk $iep $hlf $googl $twtr $aapl $cake $exel $hd $hiiq $hun $jpm¡­|rt AT_USER why twitter $vrx $teva $agn $myl $ko $brk $hlf $iep
2017-03-01: $amgn to present new kyprolis data at the 16th international myeloma workshop |rt AT_USER just out rbc - march madness: "reading the biotech yee-leaves" for 10 key upcoming events $amgn $vrtx $pbyi $r
2017-03-02: don't think carl didn't see these tweets! legal resolutions closer! $vrx $agn $myl $mrk $teva $spy $spx $amgn $blue¡­ |$amgn oi for maturity 03/03/2017. 167.50 highest put. 167.50 highest call.  |amge